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A number of organelles contained within mammalian
cells have been implicated in the selective sequestration
of chemical entities including drug molecules. Specifi-
cally, weakly basic molecules have been shown to selec-
tively associate with either the mitochondrial compart-
ment or lysosomes; however, the structural basis for this
differentiation has not been understood. To investigate
this, we have identified a series of seven weakly basic
compounds, all with pKa near neutrality, which have
different sequestration sites within the multidrug-re-
sistant HL-60 human leukemic cell line. Three of the
compounds were selectively sequestered into the mito-
chondria of the cells, whereas the remainder were pre-
dominantly localized within lysosomes. Using specific
chemical inhibitors to disrupt either mitochondrial or
lysosomal accumulation capacity, we demonstrated that
accumulation of these compounds into respective or-
ganelles are not competitive processes. Comparison of
the permeability characteristics of these compounds as
a function of pH revealed striking differences that cor-
relate with the intracellular sequestration site. Only
those compounds with significantly reduced permeabil-
ity in the ionized state relative to the un-ionized state
had the capacity to accumulate within lysosomes. Alter-
natively, those compounds with relatively pH-insensi-
tive permeability selectively accumulated into mito-
chondria. Using novel quantitative assays for assaying
drug accumulation into subcellular organelles, we dem-
onstrated a correlation between these permeability
characteristics and the lysosomal versus mitochondrial
accumulation capacity of these compounds. Together,
these results suggest that the selective accumulations of
weakly basic compounds in either lysosomes and mito-
chondria occur via exclusive pathways governed by a
unique permeability parameter.
The development of the multidrug-resistant (MDR)1 pheno-
type in cancer cells is associated with a variety of physiological
and biochemical changes (1, 2). Our laboratory investigated the
intracellular drug sequestration pathways associated with the
emergence of this drug-resistant phenotype. We have recently
shown that selective accumulation of anticancer drugs in cel-
lular organelles of the MDR human leukemic cell line HL-60
can be associated with decreased drug effectiveness (3). More-
over, we also have shown that different organelles are able to
sequester drugs with different structural attributes according
to independent mechanisms. A remaining paradox in this field
of research has to do with the intracellular sequestration site of
weakly basic compounds. We along with others have shown
that certain weakly basic compounds (i.e. daunorubicin, doxo-
rubicin) with pKa values near neutrality are selectively seques-
tered into lysosomes of MDR cell lines (3, 4). Alternatively,
other weakly basic compounds, also with pKa near neutrality,
specifically accumulate within the mitochondria of cells (i.e.
rhodamine 123) (5). Independent theories have been put forth
to describe weak base sequestration into each of these compart-
ments; however, a physicochemical parameter that can be used
to predict the intracellular sequestration site has not been
elucidated.
Selective accumulation of weakly basic drugs into the lyso-
somal compartment of MDR cells is thought to occur according
to a pH partitioning type of mechanism that relies on the low
pH of lysosomes relative to the cell cytosol (6–8). In the MDR
HL-60 cell line, we have previously determined that the pH
values associated with the lysosomal lumen and cell cytosol are
5.2 and 7.1, respectively (3). Following permeation through the
cell membrane, weakly basic drugs with pKa near neutrality
would exist to a significant degree in their un-ionized mem-
brane-permeable form in the cytosol. In this form, they are able
to diffuse through the lysosomal lipid bilayer and enter the
lumen. Here in the acidic environment, the base would exist
predominantly in the ionized form. Because ionized forms of
drugs are traditionally thought to be membrane impermeable,
the weak base becomes trapped within the lysosome, which can
lead to significant accumulation as long as the pH gradient is
maintained.
The accumulation mechanism for weak bases into the mito-
chondrial compartment is driven by the negative membrane
potential associated with this organelle. The mitochondrial
transmembrane proton motive force, which is generated by
oxidative phosphorylation, results in both a pH differential
(more alkaline inside) and an electrical potential (more nega-
tive inside) (9). This membrane potential difference has been
estimated to be 150 to 170 mV and can result in the accu-
mulation of cationic molecules several hundred-fold over cyto-
plasmic concentrations (10).
The site of intracellular sequestration of weakly basic com-
pounds is an important consideration for effective drug target-
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ing. Drug targets are typically housed within specific cellular
compartments, and the ability of a drug to accumulate therein
has a bearing on drug activity and specificity. The quest to
specifically target novel anticancer agents to the mitochondrial
compartment has received much recent interest and many
lipophilic cationic molecules have been evaluated as anticancer
agents (11). Significant accumulation of such compounds into
the mitochondria has varied effects; nevertheless, the end re-
sult is often diminished cellular ATP production, which in turn
triggers cell death (11). From a drug delivery point of view, the
attractiveness of this therapeutic approach is centered on the
finding that cancer cells have increased negative membrane
potential relative to nontransformed cells (11). This difference
is expected to result in a 10-fold higher concentration in the
mitochondria of cancer cells than those of nontransformed
cells. Unfortunately, the design of mitochondrially targeted,
weakly basic anticancer drugs has been complicated by the fact
that many of these agents are sequestered by lysosomes, which
diminishes the aforementioned specificity. Furthermore, the
effectiveness of many traditional weakly basic anticancer
agents is also lessened as a result of lysosomal sequestration in
MDR cancer cells. Many of these agents (i.e. daunorubicin,
doxorubicin) have nuclear targets including DNA and topo-
isomerase (12). Consequently, lysosomal sequestration results
in reduced interactions with targets and decreased effective-
ness. Taken together, drug design efforts would greatly benefit
from an understanding of physicochemical parameters that
predictably influence intracellular localization.
To address this paradox we have evaluated the physicochem-
ical properties of a series of weakly basic compounds that are
preferentially sequestered into lysosomes or mitochondria. We
report here that the permeability of the ionized species relative
to un-ionized species is a principal determinant of subcellular
distribution.
EXPERIMENTAL PROCEDURES
The doxorubicin-selected resistant human acute promyeloid leuke-
mia cell line MDR HL-60 was kindly provided by Dr. Yueshang Zhang
(Arizona Cancer Center, University of Arizona). MDR HL-60 cells were
grown in RPMI 1640 medium supplemented with 10% fetal calf serum,
10 mM Hepes, 1 mM sodium pyruvate, 0.1% penicillin, and 0.1% strep-
tomycin. The cells were maintained at a density of 1  105 to 1  106
cells/ml at 37 °C in a humidified 5% CO2 atmosphere. Quinacrine
(QNC) and 2,4-dinitrophenol (DNP) were kindly provided by Dr. Moo
Cho (School of Pharmacy, University of North Carolina-Chapel Hill).
Harmine (HAR), papaverine (PAP), New Fuchsin (NF), 1-octanol and
concanamycin A (Con A) were purchased from Sigma. Lysotracker Red
DND-99 (LTR), rhodamine 123 (R123), and rhodamine 6G (R6G) were
obtained from Molecular Probes (Eugene, OR).
Fluorescence Microscopy—Cells were grown to a density of 1  106
cells/ml prior to experimentation. The cells were incubated with the
indicated compound (1 M) for 2 h under normal growth conditions.
Following incubation, the cells were pelleted (1000 rpm, 5 min) and
washed twice with ice-cold PBS to remove any unincorporated com-
pound. Disruption of lysosome-to-cytosol pH gradient was achieved
with a 24-h pre-incubation with 20 nM Con A. Disruption of mitochon-
drial membrane potential was achieved with a 30-min pre-incubation of
cells with 100 M DNP. The cells were viewed with a microscope (Leica
Diaplan, Leitz Weltzar, Germany) equipped for epifluorescence with a
100 objective, and images were captured using an Orca ER camera
(Hamamatsu Corp.) controlled by SimplePCI imaging software (Compix
Inc.). R6G and LTR utilized a Texas Red filter set, whereas a fluorescein
filter set was employed for QNC and R123.
pH Partition Experiments—The pH partition behavior of each test
compound was evaluated in n-octanol/buffer systems using the shake-
flask method (13). Briefly, the test compounds were dissolved to a final
concentration of 1 M in 10 ml of an aqueous solution containing 5 mM
Hepes, 5 mM ammonium acetate, 5 mM KCl, and 154 mM NaCl (300
mosM; pH 4–11 adjusted with 0.1 N NaOH or 0.1 N HCl). 1-octanol
(0.5–1.0 ml) was added, and the two-phase system was shaken (150
oscillations/min) for 30 min at 25 °C. The phases were separated by
centrifugation at 3000 rpm for 10 min. Aliquots (10–100 l) of each
phase were appropriately diluted and assayed for compound using a
PerkinElmer Life Sciences LS50B spectrofluorometer. Intrinsic parti-
tion coefficients of ionized (PCi) and un-ionized base (PCu) were ob-
tained by curve fitting the pH partition profiles for QNC, LTR, HAR,
and PAP using SigmaPlot 2001 (SPSS Inc., Chicago, IL) using the Hill
equation (4 parameters). For NF, R123, and R6G, PCi and PCu were
estimated as partition coefficients at pH values 3 units below and above
the pKa, respectively. The ratio of PCi to PCu was defined as the  value.
Log p values for test compounds were obtained by taking the common
logarithm of the corresponding PCu.
pKa Determinations—The pKa values for QNC, LTR, HAR, and PAP
were obtained by curve fitting the respective pH partition profiles as
described under “pH Partition Experiments.” The pKa values for the
rhodamine derivatives were obtained by monitoring the change in flu-
orescence emission as a function of pH. Buffer composition was identi-
cal to that used for pH partition experiments. Fluorescence measure-
ments were made using a PerkinElmer Life Sciences LS50B
spectrofluorometer. The excitation and emission wavelengths used for
R123 were Ex  508 and Em  525 nm and for R6G, Ex  528 and
Em  551 nm. The pH versus fluorescence emission profiles were mod-
eled using SigmaPlot 2001 with the Hill equation (4 parameters), and
the pKa value was obtained. The pKa value for NF was obtained by
monitoring the change in absorbance at 542 nm as a function of pH.
Buffer composition was identical to that used for pH partition experi-
ments. Absorbance measurements were made using a Shimadzu UV-
2401 PC spectrophotometer. The pH versus absorbance profile was
modeled using SigmaPlot 2001 with the Hill equation (4 parameters),
and the pKa value was obtained.
Isolation of Lysosomes from MDR HL-60 Cells—Lysosomes were
isolated using a magnetic chromatographic approach described by Di-
ettrich et al. (14) with modifications. Superparamagnetic iron dextran
particles (FeDex) were prepared as described therein. MDR HL-60 cells
(200  106 cells) were incubated with FeDex particles (2 mg/ml) for 1 h
at 37 °C in PBS, pH 7.4, to allow for endocytic uptake. Following the
initial 1-h incubation, the cells were washed four times with PBS and
incubated in FeDex-free medium at 37 °C for 24 h to allow for the
specific lysosomal association of FeDex particles. At the end of the
chase, the cells were washed twice with ice-cold PBS and homogenized
in 2 ml of hypotonic buffer containing 15 mM potassium chloride, 1.5 mM
magnesium acetate, 1 mM dithiothreitol, and 10 mM Hepes (pH 7.4)
supplemented with 0.1 mM phenylmethylsulfonyl fluoride, 0.5 mg/ml
DNase I, and 1 g/ml each aprotinin, leupeptin, and pepstatin. The cells
were homogenized in a Dounce homogenizer (15 strokes) using the tight
fitting pestle (pestle B). To the homogenate was added 0.5 ml of hyper-
tonic buffer containing 375 mM potassium chloride, 22.5 mM magnesium
acetate, 1 mM dithiothreitol, and 220 mM Hepes at pH 7.4 and centri-
fuged at 1750 rpm for 10 min to pellet the nuclei and unbroken cells.
The resultant post-nuclear supernatant was passed through a mini-
Macs column (Miltenyi Biotec) contained in a magnetic sleeve. The
column had been equilibrated previously with 500 l of 0.5% bovine
serum albumin in PBS. Without letting the column go dry, two column
volumes of PBS containing 0.5 mg/ml DNase I were allowed to pass
through the column and then allowed to stand in the column for 10 min.
The column was then washed with 500 l of ice-cold PBS. The column
contents were eluted with PBS containing 0.5% Triton X-100 that was
allowed to stand for 10 min prior to removal of the column from the
magnet. The eluted fraction was highly enriched in lysosomes without
detectable contamination from other cellular organelles. Approximately
29% of the total cellular lysosomes were recovered in this fraction (see
Fig. 9 of supplementary data) as evaluated using enzyme assays de-
scribed by Ford et al. (15).
Isolation of Cytosol from MDR HL-60 Cells—Cytosol isolation was
carried out according to a procedure described previously by our labo-
ratory (16). Recovery of cytosol in the isolated fraction was 100% based
on this method.
Isolation of Mitochondria from MDR HL-60 Cells—A differential
centrifugation method was developed to obtain an enriched fraction of
mitochondria with minimal lysosomal contamination. Briefly, 2 ml of
post-nuclear supernatant was generated from 200  106 MDR HL-60
cells as described under “Isolation of Lysosomes from MDR HL-60
Cells.” The post-nuclear supernatant was placed on top of a 1 M sucrose
layer (2 ml) and centrifuged at 3250 rpm for 15 min. The resultant
pellet was enriched in mitochondria without significant contamination
from other organelles. This pellet contained 23% of total cellular
mitochondria as evaluated using enzyme assays (Fig. 9 of supplemen-
tary data).
Quantitation of Compounds in Cytosol, Mitochondria, and Lysosome
Fractions—Cytosol, mitochondria, and lysosomes were isolated from
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MDR HL-60 cells incubated previously with compound for 12 h. Each of
these isolated cellular fractions was vortexed for 30 s with 600 l of
acetonitrile and centrifuged at 13,200 rpm for 5 min. The supernatant
was evaporated to dryness, and the residue was dissolved in 100 l of an
appropriate HPLC mobile phase and analyzed. The amount of com-
pound extracted from each isolated cellular fraction was thus
quantitated.
Extraction efficiencies of each compound from cytosolic, lysosomal,
and mitochondrial fractions were separately determined and incorpo-
rated in our calculations. This is done to account for the loss of com-
pound from each isolated cellular fraction during the extraction proce-
dure. Extraction efficiencies and standard curves were determined by
spiking known amounts of each test compound (5 different amounts,
representing high, medium, and low concentrations) into blank cellular
fractions and carrying out the extraction procedure described in the
previous paragraph. Standard curves were linear with r2  0.98. Ex-
traction efficiencies for all the test compounds ranged from 50 to 95%.
To compare lysosomal accumulation between compounds, the
amount of each compound in lysosomes (per cell) was divided by that in
cytosol. This value was defined as the extent of lysosomal accumulation.
This was done to account for the intrinsic permeability differences
between compounds. Similarly, the extent of mitochondrial accumula-
tion for each compound was obtained by dividing the amount of
compound in mitochondria (per cell) to that in cytosol. To compare
lysosome versus mitochondrial accumulation of compounds, the extent
of lysosomal accumulation was divided by the extent of mitochondrial
accumulation. In all the quantitative calculations, organelle isolation
efficiencies (lysosomes, 29%; mitochondria, 23%; and cytosol, 100%)
were incorporated.
HPLC Analysis—A Waters 600E system controller, 616 pump, and
717 plus autosampler comprised the HPLC system. A Waters Xterra®
MS C18 column was used. The mobile phase contained acetonitrile in 10
mM ammonium formate (pH 4.0). The percent composition of acetoni-
trile in the mobile phase for each compound was as follows: 20% for
HAR, 22% for PAP, 25% for QNC and R123, 28% for LTR and NF, and
40% for R6G. In addition, the mobile phase for R6G consisted of 20%
methanol. A 474 fluorescence detector (Waters Corp., MA) was used to
detect R123, R6G, HAR, LTR, and QNC. The excitation and emission
wavelengths for the fluorescent compounds were as follows: HAR
(Ex  350 nm; Em  427 nm), QNC (Ex  463 nm; Em  500 nm),
R123 (Ex  508 nm; Em  525 nm), LTR (Ex  577 nm; Em  590
nm), and R6G (Ex  528 nm; Em  551 nm). PAP and NF were de-
tected using a Rainin Dynamax absorbance detector (Model UV-C) at
248 nm and 542 nm, respectively.
RESULTS
Model Compound Selection—The determination of relevant
physicochemical parameters that influence lysosomal versus
mitochondrial accumulation was achieved by evaluating a se-
ries of seven weakly basic compounds. The structures of these
compounds are shown in Fig. 1. R123 and R6G are fluorescent
vital stains that have been shown to specifically associate with
the mitochondrial compartments of these cells. QNC and LTR
are fluorescent compounds that have been shown to specifically
accumulate within the lysosomes of cells. To the best of our
ability, we selected weakly basic compounds for this evalua-
FIG. 1. Structures of weakly basic compounds evaluated in this study. QNC and LTR are fluorescent molecules that selectively
accumulate within the lysosomes of cells. R123 and R6G are fluorescent molecules that accumulate in the mitochondrial compartments of cells.
HAR, PAP, and NF are weak bases with unknown intracellular distribution.
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tion, which had comparable pKa values that are near neutral-
ity. This is an important consideration, because the pKa of the
weak base would be expected to predictably influence both
lysosomal and mitochondrial accumulation behavior. The ex-
perimentally determined pKa values for each of these com-
pounds are shown in Table I. In addition to the above com-
pounds, we selected the weak bases HAR, PAP, and NF, all of
which had pKa values near neutrality; however, their intracel-
lular distribution profiles were unknown.
Evaluation of Sequestration Sites and Mechanisms—The fact
that QNC, LTR, R123, and R6G (Fig. 1) are fluorescent allowed
us to characterize their intracellular distribution using fluores-
cence microscopy. MDR HL-60 cells incubated with these com-
pounds displayed distinct punctate intracellular accumulation
patterns indicating the propensity for organelle sequestration
(See Fig. 2, top row). Using either fluorescein isothiocyanate- or
TRITC-labeled dextran, we have independently confirmed that
LTR and QNC colocalize with lysosomes; R123 and R6G were
shown to colocalize with fluorescent mitochondrial vital stains
Mitotracker Red or Mitotracker Green (representative micro-
graphs are shown in Fig. 6 of supplementary data). We have
shown previously that treatment of MDR HL-60 cells with Con
A, a specific vacuolar V-ATPase inhibitor, causes lysosome pH
to increase from 5.2 to 7.10, which results in a decrease in the
lysosome-to-cytosol pH differential. When Con A-treated cells
are incubated with LTR and QNC, the lysosomal accumulation
is significantly disrupted, consistent with the proposed mech-
anism for lysosomal accumulation of these compounds (Fig. 2,
middle row). The mitochondrial accumulation of R123 and R6G
are not visibly affected by Con A treatment. DNP is an agent
that has been shown to specifically disrupt the mitochondrial
membrane potential (17). Cells pretreated with DNP had a
significantly reduced capacity to sequester R123 and R6G into
the mitochondrial compartment, whereas this treatment did
not significantly influence the lysosomal sequestration of LTR
and QNC. It is important to note that in Con A-treated cells,
LTR and QNC are diffusely localized within the cell and are
not, by default, taken up into the mitochondrial compartment.
Likewise, R123 and R6G did not accumulate into lysosomes
even when the mitochondrial membrane potential was dis-
rupted with DNP. Con A and DNP treatments could potentially
alter lysosome and mitochondria morphology, respectively,
thereby confounding our results. Immunofluorescence staining
of the lysosomal membrane protein Lamp-1 confirmed that
cells with disrupted pH gradients had lysosomal morphology
similar to cells without pH disruption. Similarly, immunofluo-
rescence staining of the mitochondrial membrane protein Hsp
60 confirmed that disruption of mitochondrial membrane po-
tential with DNP did not visibly affect the morphology of mi-
tochondria (see Fig. 7 of supplementary data). Furthermore, we
have confirmed that Con A treatment does not result in redis-
tribution of R123 into lysosomes. Likewise, QNC does not re-
distribute into mitochondria following DNP treatment (see Fig.
8 of supplementary data).
Together these data confirm the role of membrane potential
in the mitochondrial sequestration of R123 and R6G as well as
the lysosome-to-cytosol pH differential in the lysosomal seques-
tration of LTR and QNC. More importantly, these data suggest
that the sequestration mechanisms are independent of one
another and are not competitive events in the time frame of
experimental observation.
The Role of Weak Base Permeability Characteristics—
Weakly basic compounds can exist in the un-ionized or ionized
form depending on the pH of their environment and the pKa of
the basic functionality. It is routinely thought that ionized
compounds have reduced permeability across lipid bilayers
relative to un-ionized compounds. The fact that mitochondrial
accumulating compounds failed to be sequestered into lyso-
somes in the presence of DNP led us to consider the possibility
that these compounds had unusual permeability characteris-
tics. To assess this behavior, we determined the octanol/water
partition coefficient as a function of pH for the compounds
shown in Fig. 1. Those compounds with the propensity for
lysosomal accumulation (QNC and LTR) showed a typical pro-
file for a weak base. A representative profile from this class of
compounds is shown in Fig. 3 (see QNC plot). For these mole-
cules, the ionized base (when pH  pKa) has a significantly
reduced partition coefficient relative to the un-ionized base
(when pH  pKa). In striking contrast, those compounds with
the propensity to accumulate into mitochondria (R123 and
R6G) had pH-independent partitioning behavior (See Fig. 3,
R123 for a representative profile). Using these plots we calcu-
lated a parameter that was used to quantitatively describe this
permeability behavior. The ratio of the permeabilities of the
ionized form relative to the un-ionized form was extrapolated
from these plots and was termed .
The  values for lysosomotropic agents were very low,
whereas the values for mitochondrial accumulating compounds
were near unity (Table I). Having established this qualitative
relationship, we next embarked on establishing a quantitative
correlation between  and lysosomal accumulation. Although
fluorescence microscopy is a useful approach for observing
gross differences in cellular distribution of fluorescent com-
pounds, it is not considered to be quantitative. Therefore we
developed a novel approach to quantitate the amount of drug
TABLE I
Physicochemical properties of test compounds
Compounda Mr pKa
b Log Pb,c b,c
QNC 399.9 8.0 1.85  0.03 0.004  0.001
PAP 339.3 7.3 2.68  0.11 0.006  0.001
LTR 399.2 7.5 2.10  0.02 0.017  0.001
HAR 212.2 7.7 2.20  0.06 0.023  0.004
NF 329.4 6.9 1.96  0.03 0.72  0.07
R123 380.8 7.2 1.06  0.06 1.004  0.090
R6G 479.0 7.5 2.37  0.02 1.440  0.220
a For structure see Fig. 1.
b Experimentally determined values.
c Values are means of three determinations  S.D.
FIG. 2. The mitochondrial accumulation of R123 and R6G and
the lysosomal accumulation of QNC and LTR are driven by
independent mechanisms that are not competitive. The top row
shows fluorescence micrographs of control (untreated, none) MDR
HL-60 cells incubated with designated molecules. Both LTR and QNC
selectively accumulate with the cell lysosomes, whereas R123 and R6G
are sequestered into the mitochondrial compartment of the cell. The
cells displayed in the middle row have been pretreated with the vacu-
olar ATPase inhibitor Con A. This treatment disrupts the lysosomal
sequestration of LTR and QNC but has no effect on the mitochondrial
accumulation of R123 and R6G. The cells displayed in the bottom row
have been pretreated with DNP, which selectively disrupts mitochon-
drial membrane potential. Under these conditions, mitochondrial se-
questration of R123 and R6G is prevented, whereas this treatment has
no effect on the lysosomal sequestration of LTR and QNC.
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contained within the lysosomes. This technique utilizes a
pulse-chase of cells with FeDex particles. Following the chase
period, the endocytosed dextran was specifically accumulated
within the lysosomes of cells. The cells were subsequently
incubated with drug, homogenized, and passed through a mag-
netic column that retains lysosomes containing FeDex particles
and drug. Drug contained within the lysosomes was then ex-
tracted and subsequently analyzed by HPLC. As mentioned
earlier, the amount of compound accumulated in lysosomes was
normalized to that in cytosol to account for the intrinsic per-
meability differences between the compounds. Isolation of cell
cytosol from MDR HL-60 cells was carried out by a centrifuga-
tion procedure developed previously by our laboratory (16). The
lysosome-to-cytosol accumulation ratio for each of the fluores-
cent compounds, previously evaluated qualitatively (Fig. 2),
was then plotted against their respective  values. As shown in
this plot (Fig. 4), lysosomal accumulation correlated well with
experimentally determined  values in an inverse relationship.
Furthermore, R123 and R6G failed to achieve significant lyso-
somal accumulation even after DNP pretreatment, thereby
supporting our qualitative results from fluorescence micros-
copy evaluations (data not shown).
The fact that the high  compounds R123 and R6G prefer-
entially accumulated in the mitochondria (Fig. 2) led us to
investigate if the  value of a weak base could be used to predict
its lysosomal versus mitochondrial accumulation behavior. Our
hypothesis was that compounds with low  values (near 0)
accumulate predominantly in the lysosomes. Conversely, those
compounds high in  values (near 1) accumulate predomi-
nantly in the mitochondria. To test this hypothesis, we devel-
oped a method to quantitate mitochondrial accumulation of the
compounds in MDR HL-60 cells. Isolation of an enriched mito-
chondrial fraction was accomplished using a differential cen-
trifugation approach. Using enzyme assays, we demonstrated
that mitochondrial contamination of the lysosomal fraction was
minimal and vice versa (see Fig. 9 of supplementary data).
Drug contained within the mitochondrial pellet was extracted
and quantitated using HPLC. The ratio of the amount of each
compound in the lysosomes to that in the mitochondria was
then plotted against the  values of the compounds. A complete
listing of calculated  values for compounds evaluated in this
study are shown in Table I. These results presented in Fig. 5
demonstrated a good correlation between  and lysosomal ver-
sus mitochondrial accumulation. Compounds with low  values
(i.e. QNC) had a higher propensity to accumulate within lyso-
somes (ratio 1). Conversely, those compounds with high 
values (i.e. R123) were shown to significantly accumulate
within the mitochondrial compartment of the cell (ratio 1).
Furthermore, the weak bases PAP, HAR, and NF, with previ-
ously undefined intracellular distribution, followed a trend con-
sistent with our hypothesis.
DISCUSSION
We demonstrated here a relationship between a physico-
chemical parameter of weakly basic compounds and their in-
tracellular localization site. Christian De Duve, credited with
the initial discovery of lysosomes, had published a commentary
describing the theoretical basis for lysosomal accumulation of
weak bases (18). In his work, he speculated that the weak bases
with pKa near neutrality are the best substrates for lysosomal
trapping based on a pH partitioning mechanism. Thus, based
on our pH measurements in the MDR HL-60 cell line, all of the
compounds shown in Fig. 1 are expected to achieve significant
lysosomal accumulation. However, delocalized lipophilic cati-
onic compounds, such as R123 and R6G, despite having pKa
near neutrality do not appear to significantly accumulate
within the lysosomes of the cell. Alternatively, these com-
pounds preferentially accumulate in the mitochondrial com-
partment. The driving force for mitochondrial accumulation of
these high  compounds is thought to be the negative mem-
brane potential associated with this organelle relative to the
FIG. 5. Experimentally determined  values correlate with ly-
sosomal versus mitochondrial accumulation. The bars represent
the ratio of the amount of each test compound in lysosomes
(AmountLYSO) to that in mitochondria (AmountMITO) plotted against the
respective  values. The compounds are identified above each bar. The
accumulation ratio for each compound is an average of three
experiments  S.D.
FIG. 3. Compounds selectively accumulated into the mito-
chondria of the cells have pH-independent partitioning coeffi-
cients. Conversely, compounds accumulating into the lysosomal
compartment have typical pH-dependent partitioning coeffi-
cients. A plot of the observed o/w partition coefficient as a function of
pH has been compiled for each compound shown in Fig. 1. QNC (closed
circles) is a representative profile from the class of molecules specifi-
cally associated with lysosomes; the solid line represents the sigmoidal
curve fit to the data. R123 (open circles) is a representative profile from
compounds specifically accumulated within mitochondria. The ratio of
partition coefficients in the ionized form relative to the un-ionized form
are extrapolated from these plots and presented in Table I (). All data
points represent the average of three determinations  S.D.
FIG. 4. Experimentally determined  values correlate with the
extent of lysosomal accumulation. The bars represent the amount
of each test compound in lysosomes (AmountLYSO) normalized to that in
cytosol (AmountCYTO) plotted against the respective  values. The com-
pounds are identified above each bar. The accumulation ratio for each
compound is an average of three experiments  S.D.
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potential existing in the cytosol of the cell. The apparent selec-
tive accumulation of R123 and R6G into the mitochondrial
compartment with no significant lysosomal sequestration can
be rationalized in at least two ways. First, accumulation occurs
simultaneously in both compartments with a kinetically fa-
vored mitochondrial accumulation. Alternatively, compounds
possess physicochemical attributes that make them poor sub-
strates for lysosomal sequestration. Our results favor the latter
explanation. In Fig. 2 we show that R123 and R6G fail to
appreciably accumulate into lysosomes even in the presence of
DNP, a mitochondrial membrane potential-disrupting agent.
This result is also supported through quantitative comparisons
of the lysosomal accumulation for R123 and R6G with and
without DNP pretreatment. Under these conditions, there was
no significant change in the extent of lysosomal accumulation
(data not shown). As a control, we showed that DNP has no
influence on the lysosomal accumulation of LTR and QNC. Our
results, which identified R123 and R6G as compounds that
failed to accumulate into lysosomes despite the fact that they
were both weakly basic and nearly had pKa neutrality, were
intriguing. Attempting to reconcile the basis for the lack of
lysosomal sequestration of R123 and R6G, several important
factors were considered. First, we reasoned that R123 and R6G
should be able to partition into the lumen of the lysosome. This
was because the intrinsic permeability values of the un-ionized
forms of these compounds were good and comparable with the
known lysosomotropic compounds (see Table I, log P values). In
fact R6G had a higher log P value than QNC. We also con-
cluded, based upon the experimentally determined pKa values
and lysosomal pH, that these molecules should be 99% ion-
ized when contained within the lumen of lysosomes. From
these conclusions, we believe that the difference must be that
R123 and R6G can diffuse out of the lysosome in their ionized
forms, whereas QNC and LTR cannot. This difference is man-
ifested in the plot of partition coefficient as a function of pH
shown in Fig. 3. R123 and R6G have unexpected profiles in
which the partition coefficient does not significantly change
upon ionization of the molecule. To quantitatively express this
characteristic, we extrapolated  values from the profiles rep-
resented in Fig. 3. The  value represents a novel physicochem-
ical parameter that has received little previous attention in the
literature. We show here for the first time the relevance of this
parameter in the biological distribution properties of ionizable
weakly basic compounds. Reymond et al. (19) have published
previously on the influence of charge delocalization on the
partition coefficients of ionizable weakly basic compounds.
They have demonstrated using cyclic voltametry that charge
delocalization results in reduced solvation capacity in aqueous
environments. This in turn reduces the free energy of transfer
from an aqueous environment to a lipid-like environment,
which is manifested by increased octanol-water partition coef-
ficients for delocalized ionized bases. This is in agreement with
the results presented in our study. As can be inferred from the
structures of compounds in Fig. 1, R123 and R6G have a large
degree of delocalization and maintain good membrane perme-
ability even when they exist predominantly in the ionized form.
Alternatively, the ionized forms of QNC and LTR have more
localized positive charges, which limit their permeability
through lysosomal lipid bilayers.
In our quantitative evaluations, we show an inverse correla-
tion between  and the extent of lysosomal accumulation (Fig.
4). In addition, comparison of lysosomal versus mitochondrial
accumulation (Fig. 5) reveals that an increase in  value not
only decreases the extent of lysosomal accumulation but also
results in an increase in mitochondrial accumulation. It is
noteworthy to mention that a set of weakly basic compounds
(PAP, HAR, and NF) with pKa near neutrality and previously
undefined intracellular localization follow a trend consistent
with our hypothesis (Fig. 5). Finally, our results suggest that
the  value can be used to predict the lysosomal versus mito-
chondrial accumulation tendency. To our knowledge, this work
represents the first time that a quantitative approach was
successfully used to correlate the physicochemical properties of
a compound with its intracellular distribution site.
The findings presented in this manuscript suggest that rel-
atively simple physicochemical measurements can provide a
means to evaluate, a priori, the propensity for lysosomal versus
mitochondrial accumulation of weakly basic compounds incu-
bated with cells. Such findings should be extremely valuable
for screening compounds obtained from a large library of drug
candidates. Likewise, this information can be useful in the
theoretical design of drugs with favorable subcellular localiza-
tion sites and thus improved specificity and activity.
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